The safety of ABO minor incompatible platelets transfusions using a rapid infuser

Transfusion. 2024 Mar;64(3):449-453. doi: 10.1111/trf.17739. Epub 2024 Feb 1.

Abstract

Background: Administering platelets through a rapid infuser is proven to be safe. However, the clinical significance of infusing ABO-incompatible platelets with red blood cells (RBCs) in a rapid infuser remains unclear. There is a theoretical risk that isoagglutinin in the plasma of a platelet unit can interact with RBCs and induce hemolysis.

Materials and methods: Seven in vitro studies were performed including five cases (type A RBCs and type O platelets) and two controls (type A RBCs and platelets). Anti-A titers were measured in platelet units. An RBC unit and a platelet unit were mixed in the rapid infuser reservoir and incubated for 30 min. The primary outcome was the presence of hemolysis based on the following parameters: free hemoglobin concentration, hemolysis check, direct antiglobulin test (DAT), and direct agglutination.

Results: The post-mix DAT was positive for IgG in all test samples (5/5), and weakly positive for complement in 3/5. The changes in free Hb in test cases between measured and calculated post-mix spanned -2.2 to +3.4 mg/dL. Post-mix hemolysis check was negative in 3/5 and slightly positive in 2/5 cases, with no significant differences compared to the control case. Anti-A titers ranged from 16 to 512 and were not associated with hemolysis. All samples were negative for direct agglutination.

Conclusion: Our study suggested that mixing ABO-incompatible platelets with RBCs in a rapid infuser does not induce in vitro hemolysis. These findings support the use of rapid infusers regardless of platelet compatibility in support of hemostatic resuscitation.

Keywords: hemolysis; massive hemorrhage protocols; massive transfusion protocols; mixing incompatible blood components; rapid infusion system.

MeSH terms

  • ABO Blood-Group System*
  • Antibodies
  • Blood Group Incompatibility
  • Blood Platelets
  • Hemolysis*
  • Humans
  • Platelet Transfusion / adverse effects

Substances

  • ABO Blood-Group System
  • Antibodies

Grants and funding